跳至主要内容
临床试验/CTRI/2023/05/052737
CTRI/2023/05/052737尚未招募2 期

Randomized control trial of addition of Aspirin to standard care in oral cancer patients.

Banaras Hindu University0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • All Histologically proven cases of primary oral cancers.
  • Stage T1 to T4, N0 to N3, M0 to M1.
  • Age above 18.
  • Karnofskyâ?? performance status more than 70, ECOG 0 to 2
  • Hb above 8.0 gm/dL
  • Total count above 4000 cu mm
  • Platelet count above100000
  • Serum creatinine less than 1.0mg
  • Liver enzymes up to 1.5 times normal
  • Bilirubin less 1.0mg

排除标准

  • Patients with acid peptic disease
  • Pregnant and lactating women.
  • Patients not willing to participate.
  • Patients with known allergy to NSAID
  • Patients with Asthma, rhinitis and nasal polyps
  • Presence of viral fever
  • Use of any other blood thinner like warfarin, heparin or low molecular weight heparin
  • bleeding/blood-clotting disorders (such as hemophilia, vitamin K deficiency, low platelet count)
  • pyruvate kinase or G6PD deficiency
  • Patients receiving mifepristone, acetazolamide, corticosteroids, dichlorphenamide, methotrexate, valproic acid, herbal medications (such as ginkgo biloba)
  • Patients with recent history of anti-viral vaccines

研究者

相似试验